Organogenesis Holdings (ORGO) Net Income towards Common Stockholders (2016 - 2026)

Organogenesis Holdings' Net Income towards Common Stockholders history runs 11 years deep, the most recent figure standing at -$56.2 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 160.1% year-over-year to -$56.2 million in Q1 2026; TTM through Mar 2026 was -$13.1 million, a 36.0% increase from a year earlier, with the FY2025 full-year figure at $25.7 million, up 2838.74% from the prior year.
• Net Income towards Common Stockholders retreated to -$56.2 million in Q1 2026 per ORGO's latest filing, from $40.8 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $40.8 million in Q4 2025 and bottomed at -$56.2 million in Q1 2026.
• The 5-year median for Net Income towards Common Stockholders is $1.4 million (2023), against an average of -$771294.1.
• Across the five-year window, Net Income towards Common Stockholders jumped 1373.02% in 2023 and slumped 928.14% in 2025, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at $7.5 million in 2022, then sank by 80.71% to $1.4 million in 2023, then surged by 306.86% to $5.9 million in 2024, then surged by 593.82% to $40.8 million in 2025, then plunged by 237.77% to -$56.2 million in 2026.
• Per Business Quant, the three latest ORGO Net Income towards Common Stockholders figures stand at -$56.2 million (Q1 2026), $40.8 million (Q4 2025), and $14.5 million (Q3 2025).